Cargando…
Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group
SIMPLE SUMMARY: Deep (aggressive) angiomyxoma (DAM) is an extremely rare primary neoplasm of the vulva whose growth is particularly favored during pregnancy. To date, neither the origin nor the optimal management of DAM are clear, especially in pregnancy. Therefore, we present here a systematic revi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340504/ https://www.ncbi.nlm.nih.gov/pubmed/37444513 http://dx.doi.org/10.3390/cancers15133403 |
_version_ | 1785072095552602112 |
---|---|
author | Cicogna, Stefania Dellino, Miriam Miano, Salvatora Tindara Magazzino, Francescapaola Domenici, Lavinia Pignata, Sandro Mangili, Giorgia Cormio, Gennaro |
author_facet | Cicogna, Stefania Dellino, Miriam Miano, Salvatora Tindara Magazzino, Francescapaola Domenici, Lavinia Pignata, Sandro Mangili, Giorgia Cormio, Gennaro |
author_sort | Cicogna, Stefania |
collection | PubMed |
description | SIMPLE SUMMARY: Deep (aggressive) angiomyxoma (DAM) is an extremely rare primary neoplasm of the vulva whose growth is particularly favored during pregnancy. To date, neither the origin nor the optimal management of DAM are clear, especially in pregnancy. Therefore, we present here a systematic review that could be a useful tool to provide further knowledge about the behavior of and the management strategies for this rare malignancy. ABSTRACT: Deep (aggressive) angiomyxoma of the lower genital tract is a rare malignancy affecting women of reproductive age. Being a hormone-sensitive tumor, its growth is particularly benefitted during pregnancy. Surgical excision with complete resection is indicated, even if a wait-and-see approach can be considered until delivery, to avoid destructive surgeries. The mode of delivery is to be evaluated based on the location and size of the neoplasm; vaginal delivery is not contraindicated, as long as the tumor does not obstruct the birth canal. Positive surgical margins are the most important prognostic factor for recurrence. Adjuvant therapy with gonadotropin-releasing hormone analogues may be proposed after pregnancy, in the case of non-radical surgery. Despite the high local relapse rate, the outcomes for mother and child are favorable. Since recurrences can occur after many years, the patient should be included in long-term follow-up. |
format | Online Article Text |
id | pubmed-10340504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103405042023-07-14 Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group Cicogna, Stefania Dellino, Miriam Miano, Salvatora Tindara Magazzino, Francescapaola Domenici, Lavinia Pignata, Sandro Mangili, Giorgia Cormio, Gennaro Cancers (Basel) Review SIMPLE SUMMARY: Deep (aggressive) angiomyxoma (DAM) is an extremely rare primary neoplasm of the vulva whose growth is particularly favored during pregnancy. To date, neither the origin nor the optimal management of DAM are clear, especially in pregnancy. Therefore, we present here a systematic review that could be a useful tool to provide further knowledge about the behavior of and the management strategies for this rare malignancy. ABSTRACT: Deep (aggressive) angiomyxoma of the lower genital tract is a rare malignancy affecting women of reproductive age. Being a hormone-sensitive tumor, its growth is particularly benefitted during pregnancy. Surgical excision with complete resection is indicated, even if a wait-and-see approach can be considered until delivery, to avoid destructive surgeries. The mode of delivery is to be evaluated based on the location and size of the neoplasm; vaginal delivery is not contraindicated, as long as the tumor does not obstruct the birth canal. Positive surgical margins are the most important prognostic factor for recurrence. Adjuvant therapy with gonadotropin-releasing hormone analogues may be proposed after pregnancy, in the case of non-radical surgery. Despite the high local relapse rate, the outcomes for mother and child are favorable. Since recurrences can occur after many years, the patient should be included in long-term follow-up. MDPI 2023-06-29 /pmc/articles/PMC10340504/ /pubmed/37444513 http://dx.doi.org/10.3390/cancers15133403 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Cicogna, Stefania Dellino, Miriam Miano, Salvatora Tindara Magazzino, Francescapaola Domenici, Lavinia Pignata, Sandro Mangili, Giorgia Cormio, Gennaro Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group |
title | Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group |
title_full | Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group |
title_fullStr | Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group |
title_full_unstemmed | Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group |
title_short | Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group |
title_sort | aggressive angiomyxoma of the lower female genital tract in pregnancy: a review of the mito rare tumors group |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340504/ https://www.ncbi.nlm.nih.gov/pubmed/37444513 http://dx.doi.org/10.3390/cancers15133403 |
work_keys_str_mv | AT cicognastefania aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup AT dellinomiriam aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup AT mianosalvatoratindara aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup AT magazzinofrancescapaola aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup AT domenicilavinia aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup AT pignatasandro aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup AT mangiligiorgia aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup AT cormiogennaro aggressiveangiomyxomaofthelowerfemalegenitaltractinpregnancyareviewofthemitoraretumorsgroup |